Alkermes plc was formed in September 2011 when Massachusetts-based Alkermes Inc merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing arm of Elan Corporation. Today, Alkermes is a fully integrated, global biopharmaceutical company, headquartered in Dublin, Ireland, that develops innovative medicines to treat central nervous system (CNS) disorders such as addiction, schizophrenia and depression. It has a portfolio of more than 20 commercial drug products and a substantial pipeline of product candidates.
A part of Alkermes’ highly diversified business is contract development and manufacturing of pharmaceutical products for third parties through Alkermes Contract Pharma Services. One of the company’s first outsourcing contracts as Alkermes plc was a multi-million dollar manufacturing deal with one of the world’s top 10 pharmaceutical companies, in which Alkermes agreed to manufacture the company’s finished pharmaceutical product in Athlone, Ireland.
Following the merger, Jim Botkin became Senior Vice President of Operations at Alkermes and oversees the company’s contract pharmaceutical services and manufacturing operations. At CPhI/ICSE Worldwide, which took place in Madrid last October, Botkin sat down with Manufacturing Chemist to discuss his current position at Alkermes and his views on the pharmaceutical industry, in which he has served for more than 40 years.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.